Navigation Links
MEDai Technology Identifies Prescription Drug Misuse
Date:7/2/2008
he improvement of healthcare delivery. Utilizing cutting-edge technology, payers and care management organizations are able to predict patients at risk, identify cost drivers for their high-risk population, forecast future health plan costs, evaluate patient patterns over time, and improve outcomes. For more information on MEDai, visit http://www.medai.com.
For More Information Contact:
Lizzy Feliciano, MBA,
Manager
Marketing & Communications
MEDai, Inc.
(800) 446-3324
'/>"/>
| SOURCE MEDai, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. MEDai Demonstrates the Value of Implementing Predictive Analytics
2. MEDai Assists Healthcare Organizations Demonstrate the Value of Predictive Modeling
3. MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award
4. Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care
5. MedAire to Provide Medical Training for Bombardier Safety Standdown
6. Virgin America Airline Debuts With MedAire Services
7. Align Technology to Announce Second Quarter Fiscal 2008 Results on July 29
8. Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology
9. BPO Management Services Wins Two New Information Technology Outsourcing Contracts
10. Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition
11. Toys and technology for rehabilitation in cerebral palsy patients
Post Your Comments:
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...
(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3[0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis[0] Research at the cutting edge of knowledge[0] Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts
... rates of hospital use, but they may be experiencing ... said in the latest edition of the Medical ... Melbourne-based Refugee Health Research Centre, Dr Ignacio Correa-Velez, and ... financial years to June 2004. ,'We found ...
... -- The science has long been clear that smoking causes ... damage from a father who smokes . ,Canadian ... in the DNA sequence of sperm cells, alterations that could ... are published in the June 1 issue of Cancer Research, ...
... market is estimated at around $2.5 trillion per annum, ... percent per annum. A radical shift in food consumption ... ,In markets, especially in the developed world, with ... is rapidly increasing. Besides, the emerging health-conscious newer generation ...
... released by a growing tumor could one day become ... chemotherapy and radiation treatment in people with advanced throat ... 1, 2007, issue of Clinical Cancer Research. ... Communication Disorders (NIDCD) and National Cancer Institute (NCI), two ...
... Researchers have found that patients with obstructive sleep apnea ... dead cells (apoptotic cells) from the lining (endothelium) of ... who do not have OSA. The finding may help ... for cardiovascular disease (CVD). ,According to the ...
... In a retrospective study of 700 patients with ... be significantly higher in HIV-infected patients compared ... TB relapse rates were higher in HIV-infected patients ... compared to those receiving daily or longer treatment. ...
Cached Medicine News:Health News:Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring 2Health News:Nutrient-rich Dairy Beverages an Emerging Market 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 3Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 4Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2Refugees No Burden On Health SystemCigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to OffspringNutrient-rich Dairy Beverages an Emerging MarketBlood Test may Help Signal Tumor's Remission, Return in Throat Cancer PatientsPatients With OSA at Higher Risk for Cardiovascular DiseaseTreatment Outcomes of Patients With HIV and Tuberculosis
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ... Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine[0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference[0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market
... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...
... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009. Gross profit was ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Transgenomic Reports Fourth Quarter Financial Results 2Transgenomic Reports Fourth Quarter Financial Results 3Transgenomic Reports Fourth Quarter Financial Results 4Transgenomic Reports Fourth Quarter Financial Results 5Transgenomic Reports Fourth Quarter Financial Results 6Transgenomic Reports Fourth Quarter Financial Results 7Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B2 Biological Safety Cabinet...
Class II Type A2 Biological Safety Cabinet...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |